- HK$292.96m
- HK$697.61m
- HK$406.86m
Annual cashflow statement for PuraPharm, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -216 | 40.2 | -117 | -119 | -102 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 180 | 21.6 | 170 | 81.9 | 73.3 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 101 | 10.5 | -118 | 77.1 | 60 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 131 | 120 | -14.5 | 88.5 | 79.6 |
| Capital Expenditures | -97 | -82.8 | -6.56 | -23.6 | -21.7 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 5.5 | -9.26 | 12.6 | -7.69 | 3.46 |
| Sale of Fixed Assets | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -91.5 | -92.1 | 6 | -31.2 | -18.2 |
| Financing Cash Flow Items | -29.6 | -40.4 | -27 | -18.6 | -35.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -79.2 | -3.61 | -16 | -35.6 | -122 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -40.1 | 25.4 | -18.3 | 16.2 | -55.7 |